Edgar Filing: Cardium Therapeutics, Inc. - Form 4

Cardium Therapeutics, Inc. Form 4 March 04, 2014								
	STATES SP	CURITIES AND EXCHANGE	COMMISSION		PPROVAL			
Check this box	51412551	Washington, D.C. 20549		OMB Number:	3235-0287 January 31,			
Subject to Section 16. Form 4 or	WNERSHIP OF	Expires: Estimated a burden hou response	2005 average irs per					
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								
(Print or Type Responses)								
1. Name and Address of Reporting LEWIS GERALD J	Sy	Issuer Name and Ticker or Trading ubol rdium Therapeutics, Inc. [CRXM	5. Relationship of Reporting Person(s) to Issuer[] (Check all applicable)					
(Last) (First) (Date of Earliest Transaction						
(Month/Day/Year) 10% Owner 11750 SORRENTO VALLEY RD., 02/28/2014Officer (give title SUITE 250 below) below)								
(Street)		f Amendment, Date Original d(Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
SAN DIEGO, CA 92150 Person								
(City) (State)	(Zip)	Table I - Non-Derivative Securities A			-			
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	Execution Dat any	3. 4. Securities , if TransactionAcquired (A) or Code Disposed of (D) ear) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price	SecuritiesFBeneficially(IOwned(IFollowing(IReportedTransaction(s)(Instr. 3 and 4)	form: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)								

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Cardium Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8		Acquired (or Dispose (D) (Instr. 3, 4 and 5)	ed of				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to purchase Common Stock	\$ 0.8	02/28/2014		J <u>(1)</u>		50,000		02/28/2014	02/28/2024	Common Stock	50,000
Donor	ting Ou	unoro									

Reporting Owners

Reporting Owner Name / Address		Relationsh	ips	
	Director	10% Owner	Officer	Other
LEWIS GERALD J 11750 SORRENTO VALLEY RD., SUITE 250 SAN DIEGO, CA 92130	Х			
Signatures				
/s/ Tyler M. Dylan-Hyde on Behalf of Mr. Lewis Attorney		03/04/2014		
** Signature of Reporting Person		Date		

**Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

"Out-of-the-money" warrants were issued with an exercise price set at a 57% premium to the closing price of the Issuer's common stock (1) on the issue date, and were acquired pursuant to a compensation and incentive arrangement in connection with which the reporting

person's compensation as a director had been deferred.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.